Franz-Werner Haas, CureVac CEO (Christoph Schmidt/picture-alliance/dpa/AP Images)

GSK, Cure­Vac forge ahead with mid-stage plans for flu, Covid mR­NA vac­cines

GSK-part­nered mR­NA biotech Cure­Vac re­leased in­ter­im Phase I da­ta on its new mR­NA vac­cines for Covid and the flu, caus­ing its stock $CVAC to jump 25%.

While the da­ta are ear­ly and main­ly ad­dress the safe­ty of the new vac­cines, Cure­Vac CEO Franz-Wern­er Haas told End­points News that re­leas­ing the in­ter­im da­ta was the biotech’s way of say­ing, “Yes, we are back in the race.”

Cure­Vac’s first at­tempt at an mR­NA vac­cine flamed out af­ter it failed its piv­otal tri­al, which Cure­Vac at­trib­uted in part to the rise of new vari­ants.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.